Brief: Atreca Posts Q4 Loss Per Share Of $0.79
03/03/2022 21:12
March 3 (Reuters) - Atreca Inc BCEL.O :
* ATRECA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL
RESULTS AND ATRC-101 DATA UPDATE
* Q4 LOSS PER SHARE $0.79
* ATRC-101 HAS BEEN WELL-TOLERATED WITH NO DOSE-LIMITING
TOXICITIES OBSERVED
* CLINICAL ACTIVITY OBSERVED IN MULTIPLE TUMOR TYPES AND
SIGNIFICANTLY ASSOCIATED WITH ATRC-101 TARGET EXPRESSION
* Q4 EARNINGS PER SHARE VIEW $-0.76 -- REFINITIV IBES DATA
* PARTIAL RESPONSE OBSERVED IN ATRC-101 MONOTHERAPY COHORT
* CONFIRMED COMPLETE RESPONSE OBSERVED IN ATRC-101 AND
PEMBROLIZUMAB COMBINATION COHORT IN PHASE 1B CLINICAL TRIAL
Source text for Eikon: ID:nGNX8vqdwV
Further company coverage: BCEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross